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Abstract Normal human lung fibroblasts were transfected with
expression plasmids encoding mot-2, an hsp70 family member
that is associated with the immortal phenotype. After the empty
vector-transfected controls had become senescent and positive for
senescence-associated L-galactosidase (SA-L-gal), the mot-2-
expressing cells continued to proliferate for an additional 12^18
population doublings and showed a young cell morphology and
much lower SA-L-gal activity. The tumor suppressor p53 was
found to be transcriptionally inactivated in life span-extended
cells. We have thus shown for the first time that overexpression
of mot-2 in normal human cells is able to permit their temporary
escape from senescence.
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1. Introduction
Normal human cells undergo a ¢nite number of cell divi-
sions and ultimately enter a metabolically active state of per-
manent growth arrest called replicative senescence [1]. Cells
can escape from the limits on their replicative capacity as a
result of various genetic and epigenetic changes that are not
completely understood. We originally cloned mortalin genes,
mot-1 and mot-2, as hsp70 family members from normal and
immortal murine cells, respectively [2,3]. Their proteins di¡er
by only two amino acid residues but exhibit di¡erent subcel-
lular localizations and have contrasting biological activity
[2,3]. Normal and transformed human cells showed pancyto-
solic and four di¡erent kinds of non-pancytosolic distribution
of the proteins [4,5]. Mortalin cDNAs isolated from two dif-
ferent human cell lines (HT1080 and HeLa) encode proteins
with di¡erent staining patterns but are identical and, similar
to mouse mot-2 cDNA, lead to malignant transformation of
NIH 3T3 cells when transfected [6]. We recently demonstrated
interaction between wild-type (wt) p53 and mot-2 protein in
mouse and human transformed cells [7]. Transfection of COS7
cells with a mot-2 expression plasmid resulted in downregula-
tion of p53-responsive genes, p21SDI1=WAF1 and mdm-2. Fur-
thermore, G1-associated nuclear translocation of p53 was ab-
rogated by mot-2. These results demonstrated that mot-2 is
able to interfere with p53 activity [7].
Loss of p53 activity has previously been shown to be an
important step in the temporary escape of human cells from
senescence (reviewed in [8]). This suggests that p53 is normally
involved in the process of senescence. In support of this, there
is evidence that the activity of p53 (both DNA binding activ-
ity and transcriptional activation) increases as cells near sen-
escence [9,10]. The expression of the p53-induced cell cycle
inhibitor p21SDI1=WAF1 also increases at senescence [11]. Ex-
pression of a dominant negative p53 mutant in normal human
diploid ¢broblasts permitted them to continue dividing for a
limited number of population doublings (PDs) beyond the
point at which their normal counterparts became senescent
[12,13]. Evidence that this e¡ect was due to loss of wt p53
function and not due to a p53 gain-of-function mutation was
provided by studies demonstrating that spontaneous loss of
p53 function in ¢broblasts from an individual with Li^Frau-
meni syndrome resulted in a substantial, but ¢nite, increase in
proliferative capacity [14]. The great majority of these cells
eventually entered a state of terminal proliferation arrest
[14]. However, inactivation of the pRb/p16INK4a pathway in
¢broblasts that have lost wt p53 function resulted in a further,
but still ¢nite, increase in proliferative potential [15,16].
There are thus at least two terminal proliferation arrest
states beyond senescence that act as a barrier to unlimited
proliferation of human ¢broblasts (reviewed in [17]). The
genes required for such proliferation barriers may be cell
type-speci¢c [18,19]. For cells to overcome the ¢nal barrier
to unlimited proliferation (i.e. to become immortalized), acti-
vation of a telomere maintenance mechanism appears to be
essential (reviewed in [20]). Although mechanisms of senes-
cence [21,22] and telomere maintenance [20] have attracted a
lot of attention, very little is known about the intermediate
proliferation barriers including the terminal arrest that even-
tually occurs in cells in which p53 function has been inacti-
vated. In addition, a substantial minority of immortalized
cells and cancers do not contain any detectable abnormalities
in the p53 gene. It is therefore of great interest to determine
whether there are other genetic changes that have the same
e¡ect on proliferative life span as loss of wt p53 function.
Here we demonstrate for the ¢rst time that overexpression
of mot-2 results in the temporary escape of normal human
diploid ¢broblasts from senescence. In addition to their in-
creased proliferative capacity, the mot-2-expressing cells had
the morphological characteristics of young ¢broblasts and
had reduced expression of senescence-associated L-galactosi-
dase. The mot-2-expressing life span-extended cells exhibited
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decreased p53 function. These results show that overexpres-
sion of mot-2 has an e¡ect on proliferative life span similar to
that reported previously for loss of wt p53, and suggest that
the e¡ects of mot-2 in this regard are mediated via their in-
terference with p53 function.
2. Materials and methods
2.1. Cell culture
Normal human lung ¢broblasts, MRC-5, were cultured in Dulbec-
co’s modi¢ed Eagle’s minimal essential medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). Cells were serially pas-
saged by 1:4 subculturing.
2.2. Transfections
Mortalin cDNAs encoding non-pancytosolic proteins were isolated
from RS-4 (spontaneously immortalized clone from CD1-ICR mouse
embryonic ¢broblasts), HT1080 (human ¢brosarcoma with activated
N-ras oncogene) and HeLa (human cervical carcinoma) cells. These
cDNAs (complete open reading frames) were cloned into the pSRK
expression vector containing the hybrid SV40-human immunode¢-
ciency virus promoter/enhancer and the neoR gene and transfected
into MRC-5 cells at PD 31 using LipofectAMINE1 (Life Technolo-
gies). Transfectants were selected in 50 Wg/ml G418-supplemented
growth medium (DMEM supplemented with 10% FBS). Clones
were initially isolated by the ring isolation method and transferred
into 3.5 cm diameter dishes and were subsequently subcultured at a
1:4 ratio in 6-cm dishes. Mot-2 expression was detected in the trans-
fectants by Western blot analysis with anti-mortalin antibody [2].
2.3. Western blot analysis
The protein sample (10 Wg) separated on an SDS^polyacrylamide
gel was electroblotted onto a nitrocellulose membrane (BA85,
Schleicher and Schuell) using a semidry transfer blotter (Biometra,
Tokyo). Immunoassays were performed with anti-mortalin (mtHSP70,
A⁄nity Bioreagents) or anti-actin (Boehringer Mannheim) antibodies.
The immunocomplexes formed were visualized with horseradish per-
oxidase-conjugated anti-mouse immunoglobulin G (IgG) (ECL kit,
Amersham Pharmacia Biotech).
2.4. Senescence-associated (SA) L-galactosidase staining
Detection of L-galactosidase activity was performed as described
[23]. Cells were washed with phosphate-bu¡ered saline (PBS, pH
7.2), ¢xed in 2% formaldehyde/0.2% glutaraldehyde in PBS or 4%
formaldehyde for 10 min at room temperature, and incubated at
37‡C with a fresh staining solution consisting of 1 mg/ml 5-bromo-
4-chloro-3-indolyl L-D-galactoside, 40 mM citric acid^sodium phos-
phate (pH 6.0), 5 mM potassium ferricyanide, 5 mM potassium fer-
rocyanide, 150 mM NaCl, and 2 mM MgCl2.
2.5. p53-mediated reporter assays
Cells were transfected with a p53-responsive luciferase reporter
plasmid, pWWP-luc (containing p21WAF1 promoter; kindly provided
by Dr. Bert Vogelstein). Cotransfections of pRL-CMV were per-
formed as an internal control to determine the e⁄ciency of transfec-
tions. Forty-eight hours after transfections, luciferase assays (Dual-
Luciferase1 Reporter Assay System) were performed. Luciferase ac-
tivity values were calculated per microgram of the protein (to equalize
for cell number) as determined by Bradford protein assay. To circum-
vent low transfection e⁄ciency of late passage cells, microinjections of
the p53-responsive L-gal reporter pRGCvfos-lacZ (a kind gift from
Dr. David Wynford-Thomas) were performed directly into the nuclei
of cells growing on coverslips using an Eppendorf semiautomated
microinjection system mounted on an inverted Zeiss microscope. Con-
trol IgG was coinjected for the identi¢cation of the injected cells.
After overnight incubation, cells were ¢xed with 4% formaldehyde
for 10 min at room temperature, washed in PBS, permeabilized with
PBS containing 0.1% Triton X-100 for 5 min on ice, washed three
times with PBS and then stained with £uorescein isothiocyanate-con-
jugated secondary antibodies to detect injected IgG and L-galactosi-
dase expression using the L-gal staining kit (Boehringer Mannheim).
Cells were viewed using a Zeiss microscope. All cells showing any
trace of blue staining were scored as positive for expression.
3. Results
3.1. Life span extension of MRC-5 cells
Expression plasmids containing cDNAs that encode mouse
and human mot-2 proteins were transfected into MRC-5 nor-
mal human diploid ¢broblasts at PD 31. Stable clones were
isolated by selection in G418-containing medium. Clones con-
taining about 200 cells were transferred into 3.5-cm dishes and
then passaged serially in 6-cm dishes with a 1:4 subculture
ratio. Expression of exogenous mot-2 cDNA was examined
by RT-PCR using a forward primer from the expression vec-
tor and a reverse primer from the mot-2 sequence that yielded
a V500-bp DNA fragment (data not shown). The ampli¢ed
DNA product was sequenced and con¢rmed to be mot-2. Two
to three mot-2-expressing clones from each transfection were
pooled to maintain adequately sized cultures for further anal-
ysis. Protein lysates from the vector-transfected control and
mot-2-transfected cells were analyzed by Western blotting,
which revealed increased expression of mot-2 in the latter
(Fig. 1). Expression level was found to be higher in hmot-
2B-derived clones. The hmot-2B construct contains a human
mot-2 cDNA with a longer 3P untranslated region than the
hmot-2A plasmid [6]. The mot-2 protein expression level was
higher in the hmot-2B transfectants than in those with hmot-
2A or the murine mot-2 expression plasmid (Fig. 1).
Serial passaging was continued until the cells permanently
stopped dividing. The cumulative PD level was calculated at
each passage. The vector-transfected control cells underwent
28 PDs from the commencement of the study before ceasing
cell division and exhibiting senescent morphology (Fig. 2A).
The murine mot-2, hmot-2A and hmot-2B transfectants
underwent 37, 38 and 45 PDs, i.e. their life span was extended
by 9, 10 and 17 PDs, respectively (Fig. 2C). In contrast to
control cells, the mot-2 transfectants had a young morphology
after 24 PDs. Morphology of these cells at 40 PDs was com-
parable to the vector-transfected control cells at 26 PDs (Fig.
2A, compare upper and lower panels). In a replicate experi-
ment vector-transfected control cells underwent 30 PDs
whereas murine mot-2, hmot-2A and hmot-2B transfectants
could proliferate for 44, 46 and 48 PDs, respectively. Thus in
Fig. 1. Western blotting with anti-mortalin antibody in control and
mot-2-transfected MRC-5 cells. A higher level of protein expression
was detected in murine mot-2, hmot-2A and hmot-2B transfectants
as compared to the untransfected and vector-transfected controls.
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the two experiments mot-2-transfected cells showed prolifera-
tive life span extension by 12^18 PDs.
The vector and mot-2 transfectants were stained for SA-L-
gal that has been shown to be typical of senescent cells in
culture [23]. Vector-transfected cells showed intense SA-L-gal
staining at PDs 26 and 28 (Fig. 2B, a and b). However, mur-
ine mot-2 (not shown), hmot-2A (Fig. 2B, c and d) and hmot-
2B (Fig. 2B, f and g) derivatives at comparable PDs had far
fewer SA-L-gal-positive cells. An increase in the number of
cells with SA-L-gal staining was observed from PDs 28 to
36 and from 28 to 43 in hmot-2A and hmot-2B derivatives,
respectively, but the intensity of staining in the mot-2 trans-
fectants was less than in the vector-transfected controls at all
PDs analyzed.
3.2. Life span-extended cells showed transcriptional
inactivation of p53
It is known that due to its low amounts and high turnover
Fig. 2. A: Morphology of vector-transfected and hmot-2B-transfected MRC-5 cells during serial passaging. MRC-5/hmot-2B cells appeared
young as compared to the MRC-5/pSRK (empty vector-transfected controls) at PD 24 (compare b and f). MRC-5/hmot-2B cells at PDs 40^46
appeared similar to MRC-5/pSRK cells at PDs 26^28 (compare c and d with g and h). B: SA-L-gal staining in MRC/pSRK, MRC-5/hmot-2A
and MRC-5/hmot-2B cells. Decreased L-gal staining was detected in hmot-2A and hmot-2B cells as compared to the vector-transfected control
at the same PDs (compare a and b of vector-transfected cells with c and d of hmot-2A, and f and g of hmot-2B-transfected cells). C: In vitro
population doublings of MRC-5 cells transfected with empty vector (pSRK), murine mot-2 (pSRK/mot-2), hmot-2A (pSRK/hmot-2A) and
hmot-2B (pSRK/hmot-2B) cDNAs. Cells were transfected at PD 31. G418-selected vector, murine mot-2, hmot-2A and hmot-2B clones under-
went 28, 37, 38 and 45 PDs amounting to a total in vitro life span of 59, 68, 69 and 76 PDs, respectively.
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wt p53 protein in normal cells is not detected on Western
blots. In contrast, the mutant p53 protein is easily detected
due to its long half-life. Mock-, vector- and mot-transfected
clones had undetectable levels of p53 on Western blotting
(data not shown) suggesting its wild-type status and that the
life span extension is not caused by mutational loss of p53
function. We next analyzed p53 activity by p53-responsive
reporter assays. Vector- and mot-2-transfected cells at PD
21 were ¢rst transfected with pWWP-luc plasmid that con-
tained the p21 promoter. The p53-dependent luciferase activ-
ity was nearly ¢ve-fold higher in the vector-transfected cells
than in the cells transfected with murine mot-2, hmot-2A and
hmot-2B (Fig. 3A). When a version of the luciferase reporter
plasmid with both of the p53 binding sites deleted was used,
the vector-transfected control and mot-2-transfected cells were
seen to have comparable levels of p53-independent activity
(Fig. 3B). Since normal cells had very low transfection e⁄-
ciencies at later passages such as PD 25, we performed a
similar experiment by microinjection of a p53-dependent L-
gal reporter plasmid, pRGCvfos-lacZ (containing 13 repeats
of the p53 binding consensus sequence). About 200^250 cells
were injected and analyzed for L-gal staining in two independ-
ent experiments. Such visualization of microinjected cells and
L-gal staining revealed that whereas 90^95% of the untrans-
fected and vector-transfected cells exhibited intense p53-re-
sponsive L-gal staining, only 8^10% of the mot-2 transfectants
showed a comparable blue color (Fig. 3C). Young control
cells when similarly microinjected were seen to have less in-
tense staining (not shown). These data demonstrated in-
creased p53 transactivation activity during senescence and
its prevention by transfection and stable expression of mot-2.
4. Discussion
Mot-2 was originally cloned from mouse immortalized cells
[2,3], but it was not clear whether expression of this hsp70
family member contributes to the immortal phenotype. Im-
mortalization of human cells is usually a multistep process
that may include a ¢nite increase in proliferative life span
associated with inactivation of the p53 and pRB/p16INK4a tu-
mor suppressor gene pathways [16]. Here we show a potential
role for mot-2 in extension of proliferative life span by func-
tional inactivation of p53.
Various viral oncoproteins are also able to extend prolifer-
ative life span in part by interfering with wt p53 function. In
this regard the best known are the DNA virus oncoproteins,
SV40 large T antigen and human papillomavirus E6, each of
which binds to p53 and inactivates it (reviewed in [24]). Even
after cells have become immortalized there is a requirement
for continued inactivation of p53 and pRb [25,26]. The role of
p53 in limiting proliferative life span has been demonstrated
experimentally by showing life span extension following trans-
duction of normal diploid ¢broblasts by dominant negative
p53 mutants [12] or microinjection of anti-p53 antibodies [27].
Inhibition of expression of p33ING1, which is thought to be
required for p53 function, was shown to result in extension of
Fig. 2 (continued).
Fig. 3. Inactivation of p53 in life span-extended cells. p53-dependent
(A) and -independent (B) luciferase reporter assay in vector-, murine
mot-2-, hmot-2A- and hmot-2B-transfected MRC-5 cells at 21 PDs
after transfection. Mot-2 transfectants showed about ¢ve-fold lower
p53-dependent activity. C: p53-dependent L-galactosidase reporter
assay in vector- and hmot-2B-transfected MRC-5 cells at PD 25
after transfection. The cells were microinjected with plasmid and
rabbit IgG so that injected cells could be visualized by secondary
staining with £uorescein isothiocyanate-conjugated rabbit IgG. The
number of blue L-galactosidase-positive cells was signi¢cantly lower
in hmot-2B transfectants than in the vector-transfected controls.
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the proliferative life span of normal human ¢broblasts by
7 PDs [28]. Indirect support for this role of p53 comes from
the observation that targeting and thus inactivating both cop-
ies of the p21SDI1=WAF1 gene, a key downstream e¡ector of p53
function, resulted in a substantial extension of human ¢bro-
blast life span [29]. Mouse cells that are null for p19ARF, an
upstream activator of p53 that releases it from inhibition by
MDM2 [30,31], fail to undergo senescence [32].
We have recently reported that mot-2 inhibits the transcrip-
tional activation function of wt p53 by sequestering it in the
cytoplasm [7]. Expression of mot-2 resulted in decreased ex-
pression of the p21SDI1=WAF1 gene [7] that is normally trans-
activated by p53 [33] and upregulated at senescence [11]. Con-
sistent with this ¢nding, the p53 activity of the life span-
extended MRC-5 cells was reduced ¢ve-fold (Fig. 3). The
hmot-2B derivatives showed a higher level of expression of
mot-2 compared to the murine mot-2 and hmot-2A transfec-
tants. The life span extension for hmot-2B-transfected cells
was 17 and 19 PDs in two experiments as compared to
9 and 14 PDs for murine mot-2 and 10 and 16 PDs for
hmot-2A transfectants. This suggested that the life span ex-
tension is possibly related to the level of expression of mot-2
protein. In view of the key role of p53 in maintaining normal
proliferative potential, it seems very likely that the life span
extension e¡ect of mot-2 is mediated through inhibition of
p53 activity.
Overexpression of mot-2 in NIH 3T3 cells (that are already
immortalized) causes malignant transformation [6]. In addi-
tion to loss of normal control of proliferative life span, loss of
p53 function has other consequences (reviewed in [34,35]). It
may therefore be expected that the e¡ect of mot-2 expression
will depend on cellular genetic context.
In summary, we have shown for the ¢rst time that expres-
sion of mot-2, a gene originally cloned on the basis of its
upregulated expression in immortalized cells, is able to extend
cellular proliferative life span. This is most likely due to the
recently reported ability of mot-2 to sequester p53 in the cy-
toplasm and to inactivate it.
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